蒂尔泽帕提德的抗炎作用:一个系统的审查和元分析
Walter Masson1, Martín Lobo2, Juan P Nogueira3,4
1Department of Cardiology, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina. walter.masson@hospitalitaliano.org.ar.
Reviews in endocrine & metabolic disorders
|October 1, 2025
概括
蒂尔泽帕提德是一种双GIP和GLP-1受体激动剂,可显著降低关键炎症标记物高灵敏性C反应蛋白 (hsCRP) 和干白素-6 (IL-6). 这些发现突出了tirezepatide的作用.
科学领域:
- 药理学和治疗学 药理学和治疗学
- 免疫学和炎症 免疫学和炎症
- 代谢疾病 代谢疾病
背景情况:
- 蒂尔泽帕提德是一种双重依赖葡萄糖的胰岛素型多 (GIP) 和类似葡萄糖-1 (GLP-1) 受体激动剂,因其代谢益处和减肥能力而闻名.
- 然而,蒂尔泽帕提德的抗炎作用仍未得到广泛研究,因此需要进一步研究其对关键炎症生物标志物的影响.
研究的目的:
- 通过分析高灵敏性C反应蛋白 (hsCRP) 和中白素-6 (IL-6) 水平的变化,系统地评估蒂尔泽帕提德的抗炎作用.
- 进行现有研究的元分析,以量化蒂尔泽帕提德对不同人群和治疗方案中这些炎症标志物的影响.
主要方法:
- 按照PRISMA指南进行了系统的文献搜索,包括观察性队列研究和随机临床试验.
- 包括在内的研究报告的hsCRP和IL-6的百分比变化后的tirzepatide的管理.
- 一个随机效应模型被用于对六项符合条件的研究 (七项RCT和一项观察性研究) 的元分析.
主要成果:
- 与安慰剂相比,提尔泽帕提德显著降低了hsCRP水平 (MD: -32.9; 95% CI: -33.6 至 -32.2).
- 与安慰剂相比,使用铁泽帕提德也观察到IL-6水平的显著降低 (MD: -17.8;95% CI: -24.3至 -11.3).
- 这些降低在各种特泽帕提德剂量 (5毫克,10毫克和15毫克) 和不同研究群体中一致.
结论:
- 提尔泽帕提德的使用与关键炎症标志物hsCRP和IL-6的显著减少有关.
- 蒂尔泽帕提德的抗炎作用显而易见,无论研究的特定人群或使用的治疗方案如何.
- 这些发现增加了蒂尔泽帕提德的治疗特征,表明了超出代谢控制的潜在益处.
相关概念视频
01:29Inflammatory Bowel Disease IV: Pharmacological Management
427
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
427
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
435
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
435
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
447
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
447
01:19Antiasthma Drugs: Leukotriene Modifiers
1.7K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
1.7K
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
430
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
430
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
402
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
402